Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

January 5, 2018
Magenta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018

December 11, 2017
Magenta Therapeutics Presents Preclinical Data from Stem Cell Mobilization and Expansion Programs

December 11, 2017
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase 2 Clinical Studies

Read More News

Associated Team Members

Alexis Borisy